Post-Operative Pain - Pipeline Review, H1 2018

Publisher Name :
Date: 18-Jan-2018
No. of pages: 218
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Pipeline Review, H1 2018, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 8, 18, 8, 1, 21, 3 and 3 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).

  • The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Post-Operative Pain - Pipeline Review, H1 2018

Table of Contents

Table of Contents 2
Introduction 5
Post-Operative Pain - Overview 6
Post-Operative Pain - Therapeutics Development 7
Post-Operative Pain - Therapeutics Assessment 18
Post-Operative Pain - Companies Involved in Therapeutics Development 28
Post-Operative Pain - Drug Profiles 49
Post-Operative Pain - Dormant Projects 194
Post-Operative Pain - Discontinued Products 198
Post-Operative Pain - Product Development Milestones 199
Appendix 210

List of Tables

Number of Products under Development for Post-Operative Pain, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Post-Operative Pain - Pipeline by Abide Therapeutics Inc, H1 2018
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, H1 2018
Post-Operative Pain - Pipeline by Adynxx Inc, H1 2018
Post-Operative Pain - Pipeline by AngioChem Inc, H1 2018
Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2018
Post-Operative Pain - Pipeline by Apsen Farmaceutica SA, H1 2018
Post-Operative Pain - Pipeline by Cadila Healthcare Ltd, H1 2018
Post-Operative Pain - Pipeline by Camurus AB, H1 2018
Post-Operative Pain - Pipeline by Cara Therapeutics Inc, H1 2018
Post-Operative Pain - Pipeline by Center Laboratories Inc, H1 2018
Post-Operative Pain - Pipeline by Colby Pharmaceutical Co, H1 2018
Post-Operative Pain - Pipeline by Cytogel Pharma LLC, H1 2018
Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, H1 2018
Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H1 2018
Post-Operative Pain - Pipeline by EyeGate Pharmaceuticals Inc, H1 2018
Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp, H1 2018
Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H1 2018
Post-Operative Pain - Pipeline by Heron Therapeutics Inc, H1 2018
Post-Operative Pain - Pipeline by Immupharma Plc, H1 2018
Post-Operative Pain - Pipeline by Innocoll AG, H1 2018
Post-Operative Pain - Pipeline by Insys Therapeutics Inc, H1 2018
Post-Operative Pain - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Post-Operative Pain - Pipeline by iX Biopharma Ltd, H1 2018
Post-Operative Pain - Pipeline by Lipocure Ltd, H1 2018
Post-Operative Pain - Pipeline by Liquidia Technologies Inc, H1 2018
Post-Operative Pain - Pipeline by Lumosa Therapeutics Co Ltd, H1 2018
Post-Operative Pain - Pipeline by Medtronic Plc, H1 2018
Post-Operative Pain - Pipeline by Mundipharma International Ltd, H1 2018
Post-Operative Pain - Pipeline by Neumentum Inc, H1 2018
Post-Operative Pain - Pipeline by Novartis AG, H1 2018
Post-Operative Pain - Pipeline by Ocular Therapeutix Inc, H1 2018
Post-Operative Pain - Pipeline by Orion Corporation, H1 2018
Post-Operative Pain - Pipeline by Pacira Pharmaceuticals Inc, H1 2018
Post-Operative Pain - Pipeline by PainReform Ltd, H1 2018
Post-Operative Pain - Pipeline by Pharmaleads SA, H1 2018
Post-Operative Pain - Pipeline by PhytoHealth Corp, H1 2018
Post-Operative Pain - Pipeline by PixarBio Corp, H1 2018
Post-Operative Pain - Pipeline by RaQualia Pharma Inc, H1 2018
Post-Operative Pain - Pipeline by Recro Pharma Inc, H1 2018
Post-Operative Pain - Pipeline by Relmada Therapeutics Inc, H1 2018
Post-Operative Pain - Pipeline by Serina Therapeutics Inc, H1 2018
Post-Operative Pain - Pipeline by SteadyMed Therapeutics Inc, H1 2018
Post-Operative Pain - Pipeline by Taiwan Liposome Company Ltd, H1 2018
Post-Operative Pain - Pipeline by Teikoku Pharma USA Inc, H1 2018
Post-Operative Pain - Pipeline by Trevena Inc, H1 2018
Post-Operative Pain - Pipeline by Xigen SA, H1 2018
Post-Operative Pain - Dormant Projects, H1 2018
Post-Operative Pain - Dormant Projects, H1 2018 (Contd..1), H1 2018
Post-Operative Pain - Dormant Projects, H1 2018 (Contd..2), H1 2018
Post-Operative Pain - Dormant Projects, H1 2018 (Contd..3), H1 2018
Post-Operative Pain - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Post-Operative Pain, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Pain Management Drugs Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 93
    Pain is complex, so there are many treatment options -- medications, therapies, and mind-body techniques. This report is mainly about The drugs for pain management. The global Pain Management Drugs market was valued at US$ 35360 million in 2023 and is anticipated to reach US$ 44550 million by 2030, witnessing a CAGR of 3.3% during The forecast period 2024-2030. The leading manufacturers in The industry are GSK, Pfizer and Grunenthal, which accounted for 14.42%, 13......
  • Global Pain Management Drugs Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Pain Management Drugs market size was valued at US$ 34590 million in 2023. With growing demand in downstream market, the Pain Management Drugs is forecast to a readjusted size of US$ 43780 million by 2030 with a CAGR of 3.4% during review period. The research report highlights the growth potential of the global Pain Management Drugs market. Pain Management Drugs are expected to show stable growth in the future market. However......
  • Global Opioids Drug Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Opioids Drug market size was valued at US$ 9831.4 million in 2023. With growing demand in downstream market, the Opioids Drug is forecast to a readjusted size of US$ 8616.1 million by 2030 with a CAGR of -1.9% during review period. The research report highlights the growth potential of the global Opioids Drug market. Opioids Drug are expected to show stable growth in the future market. However, product differentiation, reduci......
  • Global Methadone Hydrochloride Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 90
    According to our LPI (LP Information) latest study, the global Methadone Hydrochloride market size was valued at US$ 63 million in 2023. With growing demand in downstream market, the Methadone Hydrochloride is forecast to a readjusted size of US$ 88 million by 2030 with a CAGR of 5.0% during review period. The research report highlights the growth potential of the global Methadone Hydrochloride market. Methadone Hydrochloride are expected to show stable growth in the future market. Howev......
  • Global Opioids Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Opioids Drugs market: According to our latest research, the global Opioids Drugs market looks promising in the next 5 years. As of 2022, the global Opioids Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescript......
  • Global Opioids Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 111
    According to our (Global Info Research) latest study, the global Opioids Drug market size was valued at USD 10340 million in 2023 and is forecast to a readjusted size of USD 9156.6 million by 2030 with a CAGR of -1.7% during review period. Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone (OxyContin®), hydrocodone (Vicodin®), codeine, morphine, and many others. The......
  • Global Methadone Hydrochloride Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 87
    According to our (Global Info Research) latest study, the global Methadone Hydrochloride market size was valued at USD 66 million in 2023 and is forecast to a readjusted size of USD 90 million by 2030 with a CAGR of 4.6% during review period. Methadone Hydrochloride is a white, crystalline material that is water-soluble. It is an opioid used to treat pain or as maintenance therapy to help with detoxification in people with opioid dependence. Market Competition is not intense, as t......
  • Global Pain Management Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 131
    According to our (Global Info Research) latest study, the global Pain Management Drugs market size was valued at USD 36380 million in 2023 and is forecast to a readjusted size of USD 45230 million by 2030 with a CAGR of 3.2% during review period. Pain is complex, so there are many treatment options -- medications, therapies, and mind-body techniques. This report is mainly about the drugs for pain management. The leading manufacturers in the industry are GSK, Pfizer and Grune......
  • Global Fibromyalgia Drugs Market Research Report 2023, Forecast to 2028
    Published: 28-Dec-2023        Price: US 2680 Onwards        Pages: 167
    The FDA has approved three drugs to treat fibromyalgia: the antidepressants duloxetine (Cymbalta) and milnacipran (Savella), plus the anti-seizure medicine pregabalin (Lyrica). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging oppo......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs